Compare Amphastar Pharmaceuticals Inc (AMPH) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Banco Santander SA trades at $14.77 (market cap $211.88B). The key difference: Banco Santander SA is far larger — about 245.2× Amphastar Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SAN | |
|---|---|---|
Market Cap | $863.95M | $211.88B |
Sector | Health | Financials |
52-Week High | $30.81 | $14.70 |
52-Week Low | $16.87 | $9.32 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Banco Santander (SAN) trades at $14.70, up 0.34% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.39, net income margin of 26.25% for 2026, and record profits in H1 2026. Recent news highlights Federal Reserve approval for its $12 billion Webster Bank acquisition, expected to close August 20, 2026, and its rise as Spain's most valuable company.
Outlook is positive given analyst consensus (64% buy ratings), solid profitability, and strategic acquisitions, but risks include regulatory scrutiny in Spain, volatile cash flows, and earnings misses in two of the last three quarters. The stock offers value with growth potential amid integration execution and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
